Zydus Lifesciences revenue and financials
₹1,154.60Change from previous close: −0.42%Absolute change: −₹4.90
In the fiscal year ended March 2026, Zydus Lifesciences reported revenue of ₹267.2B (+18.37% year over year). Net income was ₹50.4B, a net margin of 18.9%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +18.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +11.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 18.9%
- FY to Mar 2025: 20.0%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total revenue | 267,197 | 225,738 | 190,215 | 168,778 | — |
| Cost of revenue | 76,592 | 66,664 | 65,004 | 65,589 | — |
| Gross profit | 190,605 | 159,074 | 125,211 | 103,189 | — |
| Selling, general and administrative | 40,176 | 28,669 | 21,756 | 21,401 | — |
| Research and development | 5,879 | 5,332 | 1,558 | 1,358 | — |
| Operating income | 57,866 | 59,793 | 45,392 | 28,528 | — |
| EBIT | 69,861 | 61,202 | 48,529 | 27,152 | — |
| EBITDA | 83,941 | 70,360 | 56,170 | 34,379 | — |
| Interest expense | 3,650 | 935 | 440 | 1,255 | — |
| Pre-tax income | 66,211 | 60,267 | 48,089 | 25,897 | — |
| Income tax | 15,947 | 14,119 | 9,775 | 5,878 | — |
| Net income | 50,400 | 45,255 | 38,595 | 19,603 | — |
| Net income to common shareholders | 50,400 | 45,255 | 38,595 | 19,603 | — |
| Basic EPS | 50.09 | 44.97 | 38.14 | 19.30 | — |
| Diluted EPS | 50.09 | 44.97 | 38.14 | 19.30 | — |
| Average shares (basic) | 1,006 | 1,006 | 1,012 | 1,016 | — |
| Average shares (diluted) | 1,006 | 1,006 | 1,012 | 1,016 | — |